Sweet’s Syndrome Allison Dupont AM Report 1/17/06.

Slides:



Advertisements
Similar presentations
Pyoderma gangrenosum.
Advertisements

Q4: Clinical Case Conference on Human Immunodeficiency Virus Chua, Kathleen S.
NATIONAL HANSEN’S DISEASE PROGRAM NATIONAL HANSEN’S DISEASE PROGRAM.
Pityriasis rosea. pityriasis rosea is an acute,self- limited skin disease.It is characterized by the presence of rosy-coloured,round to oval macular lesions.
Melissa R. Bussey, M.D. Rheumatology Fellow
Subacute Thyroiditis And Related Disorders
Lymphadenopathy in Children
Hatem Eleishi, MD Rheumatologist STILL’S DISEASE.
1 Clinical Presentation of GPA Jessica Meikle E2-CBL 10/13/2011.
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
DESQUAMATION OF THE SKIN
Morning Report January 19 th, 2010 Jason Kidd.
Case Presentation-Dermatology Kevin T. Belasco, MSIV Touro Univ. College of Osteopathic Medicine May 24, 2004.
Serum Sickness Jill Tichy, M.D. PGY III. Serum Sickness What is it? Immunization of host (human) by heterologous (non-human) serum proteins caused by.
LEPROSY Caused by bacterium Patients are classified into infectious or noninfectious on the basis of the type and duration of disease and effects of therapy.
LT Laura Gilbert, MD, Associate CPT Nate Copeland, MD, Associate Catherine F. Decker, MD, Fellow Navy ACP Conference Walter Reed National Military Medical.
“It’s my hand, doc…” ID Case Conference Gretchen Shaughnessy, MD.
INTERSTITIAL LUNG DISEASE
Erythema By Dr. Mohamad Nasr Lecturer Of Dermatology & Venereology.
Inflammatory Bowel Disease Ulcerative colitis (UC) Kristina Blaslov Mentor: A. Žmegač Horvat.
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
ERYTHEMA NODOSUM DEFINITION-THIS IS A REACTVE DERMATOSIS THAT OCCERS IN RESPONSE TO A MYRIAD OF CONDITION CHARACTERISED BY TENDER, ERYTHEMATOOUS DEFINITION-THIS.
Erythema Multiforme. EM minor & EM with mucosal involvement Self-limited, recurrent disease, usually in young adults No or only a mild prodrome (1 to.
WEGENER’S GRANULOMATOSIS
By Dr. Zahoor 1. Question 1: 1.What is shown in the picture? 2.What is most likely cause? 2.
Erythema multiforme (EM). Erythema multiforme is a serious of acute, self-limited, recrudescent and inflammatory dermatopathy characterized by erythema,
6/17/08. Brad Weaver Sarcoidosis Multisystem & heterogeneous disease of unknown etiology characterized by noncaseating granulomas Three to four times.
بسم الله الرحمن الرحيم.
Differential Diagnosis. Staphylococcus aureus Mycobacterium marinum.
OCTOBER 27, 2011 GOOD MORNING! WELCOME APPLICANTS!
Morning Report August 4, 2009.
بسم الله الرحمن الرحيم.
Two Women with Hemoptysis Ellen Barbouche, MD Primary Care Conference 8 June 2005 NO FINANCIAL DISCLOSURE.
Differential Diagnoses. Varicella Low grade fever, anorexia, and headache Rash progresses from papules to pustulues, with significant pruritus Begins.
A Novel Presentation of 6-Mercaptopurine Toxicity in a Patient with IBD Zachary C. Junga, MD, Nisha A. Shah, MD, and John D. Betteridge,
TULSA BONE & JOINT ANTOINE (TONY) JABBOUR, MD ORTHOPAEDIC SPORTS MEDICINE SURGEON KNEE AND SHOULDER SUBSPECIALTY CHAPTER 20 PAIN SYNDROMES CHAPTER 21 NERVE.
ENDOCRINE MANIFESTATION OF MALAGNANCY PARANEOPLASTIC SYNDROME
Leprosy Ocular Erythema nodosum leprosum S.R. Rathinam FAMS PhD Uveitis service Aravind Eye Hospital Madurai.
Case No. 1 Kunkanit Suntipraron, M.D. Vesarat Wessagowit, M.D., Ph.D.
DISEASES OF SMALL INTESTINE. PLAN CROHN’S DISEASE (CD) Etiology and Etiology and Epidemiology of CROHN’S DISEASE Pathology of CROHN’S DISEASE Pathology.
C-SAF- 1 Raptiva ™ (efalizumab) Safety Richard Chin, MD Director of Clinical Research, Specialty Biotherapeutics Genentech, Inc.
 2 MAJOR GROUPS : 1. ULCERATIVE COLITIS – colon involved 2. CROHN’S DIDEASE – the hole GI tract EPIDEMIOLOGY  most common in whites than in blacks and.
Leprosy By Dr. Salam Altemimi.
Characteristics of leg ulcers 1. Venous ulceration: Often large, shallow ulcers with an irregular, ill- defined border on the lower leg & ankle. Associated.
Pathology of thyroid 2 Dr: Salah Ahmed. Thyroiditis - inflammation of the thyroid gland, includes a group of disorders characterized by some form of thyroid.
PANNICULITIS Gentleman’s Review Daniel Martingano OMSII.
MUMPS INFECTION & TROPICAL MEDICINE DIVISION. Definition : Mumps is an acute contagious disease caused by a paramyxovirus that has predilection for glandular.
Leprosy.
بسم الله الرحمن الرحيم. DRUG REACTIONS ERYTHEMA MULTIFORME ERYTHEMA NODOSUM.
Drug Eruptions Dr sami billal Md.
Stevens-Johnson Syndrome
BEHÇET’S SYNDROME (BS)
 Henoch-Schonlein Purpura
(Occulo-oral-genital syndrome)
Leprosy Ocular Erythema nodosum leprosum
Photographic Quiz 2 Medicine-1
Conjunctival Lesion – An Ocular Manifestation of a Dermatological Condition Mehreen Adhi, MD August 18, 2017.
Enteropathic Arthropathy
Behcet’s Syndrome N.Movaffagh MD Rheumatologist
BEHÇET’S SYNDROME (BS)
Henoch-Schönlein Purpura. WHAT IS Henoch-Schönlein Purpura  Also called anaphylactoid purpura  Henoch-Schönlein purpura (HSP) is the most common form.
Rachel L. Kyllo, BS, Mary Kendall Parker, MD, Ilana Rosman, MD, Amy C
Giant Cell Arteritis and Polymyalgia Rheumatica Definition
BEHÇET’S SYNDROME (BS)
Lecture 12 Gastrointestinal Disorders Inflammatory Bowel Disease
(Occulo-oral-genital syndrome)
perforation of an ileal ulcer a patient with Behçet’s disease
Dermatology Basics David Surprenant, MD.
Kawasaki disease By: Brittni McClellan.
Presentation transcript:

Sweet’s Syndrome Allison Dupont AM Report 1/17/06

Definition Sweet’s syndrome (acute febrile neutrophilic dermatosis) is characterized by: Sweet’s syndrome (acute febrile neutrophilic dermatosis) is characterized by: Fever Fever Peripheral neutrophilia Peripheral neutrophilia Painful red skin papules, nodules and/or plaques Painful red skin papules, nodules and/or plaques Neutrophilic infiltration of skin (particularly the dermis) Neutrophilic infiltration of skin (particularly the dermis)

Clinical Presentation Fever (>38˚C) can be intermittent and may precede skin manifestations by days to weeks. Fever (>38˚C) can be intermittent and may precede skin manifestations by days to weeks. Systemic symptoms may include headache, myalgia, arthralgia, and general malaise. Systemic symptoms may include headache, myalgia, arthralgia, and general malaise. Cutaneous lesions consist of erythematous to violaceous tender papules which may coalesce to form plaques. Cutaneous lesions consist of erythematous to violaceous tender papules which may coalesce to form plaques. The plaques are not pruritic. The plaques are not pruritic. Most often found on the face, neck and upper extremities (especially the dorsum of the hands), but can occur anywhere. Most often found on the face, neck and upper extremities (especially the dorsum of the hands), but can occur anywhere. Lesions on the lower extremities may resemble erythema nodosum. Lesions on the lower extremities may resemble erythema nodosum.

Clinical Presentation Oral ulcers (more common in patients with Sweet’s syndrome and a hematologic malignancy. Oral ulcers (more common in patients with Sweet’s syndrome and a hematologic malignancy. Ocular involvement (uncommon in malignancy-associated and drug-induced Sweet’s syndrome). Ocular involvement (uncommon in malignancy-associated and drug-induced Sweet’s syndrome). Conjunctivitis, episcleritis Conjunctivitis, episcleritis

Clinical Presentation Involvement of internal organs may occur leading to: Involvement of internal organs may occur leading to: Alveolitis Alveolitis Sterile osteomyelitis Sterile osteomyelitis Involvement of liver, pancreas, and/or kidneys Involvement of liver, pancreas, and/or kidneys Neurologic and psychiatric changes Neurologic and psychiatric changes

Laboratory Findings Lab findings are nonspecific. Lab findings are nonspecific. Majority will have peripheral neutrophilia. Majority will have peripheral neutrophilia. Other possible lab abnormalities include: Other possible lab abnormalities include: Elevated sedimentation rate Elevated sedimentation rate Elevated C-reactive protein Elevated C-reactive protein Leukocytosis Leukocytosis Consider evaluation of hepatic and renal function. Consider evaluation of hepatic and renal function.

Pathology Sweet’s syndrome characteristically involves dense neutrophilic infiltration of the dermis +/- dermal edema. Sweet’s syndrome characteristically involves dense neutrophilic infiltration of the dermis +/- dermal edema. Neutrophil karyorrhexis is commonly seen. Neutrophil karyorrhexis is commonly seen. There is no involvement of the vasculature of the skin and no necrosis (in contast to pyoderma gangrenosum). There is no involvement of the vasculature of the skin and no necrosis (in contast to pyoderma gangrenosum).

Diagnosis Major Criteria Abrupt onset of painful erythematous plaques or nodules. Abrupt onset of painful erythematous plaques or nodules. Histopathologic evidence of a dense dermal neutrophilic infiltrate without vasculitis. Histopathologic evidence of a dense dermal neutrophilic infiltrate without vasculitis. Minor Criteria Fever (>38˚C) Fever (>38˚C) Association with an underlying hematological/visceral malignancy, inflammatory disease, or pregnancy or preceded by an upper respiratory or GI infection or vaccination. Association with an underlying hematological/visceral malignancy, inflammatory disease, or pregnancy or preceded by an upper respiratory or GI infection or vaccination. Excellent response to treatment with systemic corticosteroids. Excellent response to treatment with systemic corticosteroids. Peripheral neutrophilia (>70% neutrophils) Peripheral neutrophilia (>70% neutrophils)

Associated Conditions Sweet’s syndrome is associated with an underlying disease or condition in up to 50% of patients. Sweet’s syndrome is associated with an underlying disease or condition in up to 50% of patients. Sweet’s syndrome may be the presenting sign and the underlying disease may not become apparent for several years after Sweet’s syndrome occurs. Sweet’s syndrome may be the presenting sign and the underlying disease may not become apparent for several years after Sweet’s syndrome occurs. There is a female predominance except in the case of malignancy-associated Sweet’s syndrome. There is a female predominance except in the case of malignancy-associated Sweet’s syndrome.

Associated Conditions 1. Malignancy Approximately 21% of patients with Sweet’s syndrome have a malignancy. Approximately 21% of patients with Sweet’s syndrome have a malignancy. 15% hematological (most commonly AML) 15% hematological (most commonly AML) 6% solid tumors (most commonly carcinomas of the GU tract, GI tract, or breast) 6% solid tumors (most commonly carcinomas of the GU tract, GI tract, or breast) 2. Infections Mostly of the upper respiratory or GI tract Mostly of the upper respiratory or GI tract Streptococcus, mycobacterium, Yersinia, Salmonella, Shigella Streptococcus, mycobacterium, Yersinia, Salmonella, Shigella

Associated Conditions 3. Inflammatory bowel disease Sweet’s syndrome may occur alone or in combination with pyoderma gangrenosum. Sweet’s syndrome may occur alone or in combination with pyoderma gangrenosum. 4. Pregnancy 5. Other conditions with a possible association: -Sarcoidosis -Rheumatoid arthritis -Thyroid disease (Grave’s disease and Hashimoto’s thyroiditis)

Drug-induced Sweet’s syndrome Criteria slightly different than classical syndrome. Criteria slightly different than classical syndrome. Temporal relationship between drug ingestion/injection and clinical presentation. Temporal relationship between drug ingestion/injection and clinical presentation. Resolution of lesions/symptoms after withdrawal of drug or treatment with corticosteroids. Resolution of lesions/symptoms after withdrawal of drug or treatment with corticosteroids.

Drug-induced Sweet’s syndrome G-CSF is responsible for the majority of cases. G-CSF is responsible for the majority of cases. Other possible causes: furosemide, lithium, hydralazine, trimethoprim- sulfamethoxazole, and oral contraceptives. Other possible causes: furosemide, lithium, hydralazine, trimethoprim- sulfamethoxazole, and oral contraceptives.

Pathogenesis Etiology of Sweet’s syndrome is unknown. Etiology of Sweet’s syndrome is unknown. Presumed to be due to a hypersensitivity reaction to an eliciting antigen which leads to stimulation of cytokine release. Presumed to be due to a hypersensitivity reaction to an eliciting antigen which leads to stimulation of cytokine release. Cytokines precipitate neutrophil activation and infiltration. Cytokines precipitate neutrophil activation and infiltration. Response to treatment with corticosteroids supports this etiology. Response to treatment with corticosteroids supports this etiology.

Pathogenesis The source of the eliciting antigen may be diverse, including bacterial, viral or tumoral antigens. The source of the eliciting antigen may be diverse, including bacterial, viral or tumoral antigens.

Treatment Gold standard: Systemic corticosteroids Gold standard: Systemic corticosteroids Start at 1 mg/kg/day prednisone with long taper (4-6 weeks) to 10 mg/day. Start at 1 mg/kg/day prednisone with long taper (4-6 weeks) to 10 mg/day. Many patients require several months of Many patients require several months of mg/day to suppress recurrences mg/day to suppress recurrences. Localized Sweet’s syndrome can sometimes be treated with high-potency topical corticosteroids. Localized Sweet’s syndrome can sometimes be treated with high-potency topical corticosteroids.

Treatment Other first-line agents include: 1. Oral potassium iodide -Systemic symptoms resolve in 1-2 days. -Dermatitis resolves in 3-5 days. 2. Colchicine -Systemic symptoms resolve in 2-3 days. -Dermatitis resolves in 2-5 days.

Alternative therapies Indomethacin Indomethacin Clofazimine Clofazimine Cyclosporine Cyclosporine Dapsone Dapsone

References Burall, Barbara M.D. “Sweet’s syndrome (acute febrile neutrophilic dermatosis)”. Dermatology Online Journal 5(1):8. Cohen, Philip R. MD, Kurzrock, Razelle MD. “Sweet’s syndrome revisited: a review of disease concepts”. International Journal of Dermatology. Volume 42, Issue 10. October Cohen, Philip R. “Sweet’s syndrome”. Orphanet. October Federman et al. “Cutaneous manifestations of malignancy”. Postgraduate Medicine Online. January Joe, Edwin K. MD. “Sweet’s syndrome”. Dermatology Online Journal 9(4):28. Moschella, Samuel L. MD. “Neutrophilic dermatoses”. UpToDate. “Sweet’s Syndrome”. Dermis.net.